The stock of Cytokinetics Incorporated (NASDAQ: CYTK) has decreased by -4.27 when compared to last closing price of 40.75.Despite this, the company has seen a gain of 4.78% in its stock price over the last five trading days. Barron’s reported on 07/19/21 that Cytokinetics Stock Is Surging. Heart-Drug Results Are Exciting Investors.
Is It Worth Investing in Cytokinetics Incorporated (NASDAQ: CYTK) Right Now?
Moreover, the 36-month beta value for CYTK is 0.80. Analysts have varying opinions on the stock, with 13 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
The average price recommended by analysts for Cytokinetics Incorporated (CYTK) is $60.38, which is $21.92 above the current market price. The public float for CYTK is 90.46M and currently, short sellers hold a 10.80% of that float. On May 24, 2023, CYTK’s average trading volume was 1.01M shares.
CYTK’s Market Performance
The stock of Cytokinetics Incorporated (CYTK) has seen a 4.78% increase in the past week, with a 1.80% rise in the past month, and a -6.54% fall in the past quarter. The volatility ratio for the week is 4.49%, and the volatility levels for the past 30 days are at 4.66% for CYTK. The simple moving average for the past 20 days is 1.77% for CYTK’s stock, with a -9.52% simple moving average for the past 200 days.
CYTK Trading at 5.76% from the 50-Day Moving Average
After a stumble in the market that brought CYTK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.09% of loss for the given period.
Volatility was left at 4.66%, however, over the last 30 days, the volatility rate increased by 4.49%, as shares surge +3.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.67% upper at present.
During the last 5 trading sessions, CYTK rose by +4.78%, which changed the moving average for the period of 200-days by -16.50% in comparison to the 20-day moving average, which settled at $38.39. In addition, Cytokinetics Incorporated saw -14.86% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CYTK starting from Blum Robert I, who sale 12,500 shares at the price of $37.41 back on May 16. After this action, Blum Robert I now owns 441,058 shares of Cytokinetics Incorporated, valued at $467,625 using the latest closing price.
HENDERSON JOHN T, the Director of Cytokinetics Incorporated, sale 4,166 shares at $37.77 during a trade that took place back on May 15, which means that HENDERSON JOHN T is holding 25,420 shares at $157,350 based on the most recent closing price.
Stock Fundamentals for CYTK
Current profitability levels for the company are sitting at:
- -342.75 for the present operating margin
- +91.12 for the gross margin
The net margin for Cytokinetics Incorporated stands at -411.21. The total capital return value is set at -56.13, while invested capital returns managed to touch -68.99. Equity return is now at value 713.60, with -45.90 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 39.41, with the company’s debt to enterprise value settled at 0.18. The receivables turnover for the company is 3.64 and the total asset turnover is 0.10. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.40.
Conclusion
To wrap up, the performance of Cytokinetics Incorporated (CYTK) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
